Recent studies have demonstrated that suppression of IGFBP2 expression mitigates FGF1-induced activation of AMPK, supporting a critical role for IGFBP2 in mediating the therapeutic effects of FGF1 on obesity-associated hepatic steatosis (26). The gene discussed is FGF1; the disease is obesity due to melanocortin 4 receptor deficiency.